BGPartner advises SynAct Pharma on its acquisition of TXP Pharma

SynAct Pharma, a Swedish listed biotechnology company has acquired all shares of TXP Pharma, a privately owned Swiss biotech company, researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases.

Through this acquisition, SynAct Pharma’s position as a leader within therapies for resolution treatment through melanocortin biology is strengthened. The acquisition gives the Swedish Pharma two platforms that complement each other and create a versatility to develop therapies to address the full range of inflammatory and autoimmune diseases. 

BGPartner has assisted SynAct Pharma in the negotiations and advised on all Swiss legal matters regarding this international m&a transaction.  The team was led by partner Oliver Gnehm (pictured left) and further consisted of partner Alain P. Röthlisberger (pictured centre) and associate Victoria Marty (pictured right).

BGPartner advises SynAct Pharma on its acquisition of TXP Pharma


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram